Comparison of Physical Properties of Untreated and Heat Treated Beech and Hornbeam

Istraživanjem fizikalnih svojstava toplinski obrađene bukovine i grabovine utvrđeno je da je njihova srednja vrijednost manja i signifikantno se razlikuje od srednjih vrijednosti fizikalnih svojstava neobrađene bukovine i grabovine. Srednja vrijednost gustoće u apsolutno suhom stanju toplinski obrađene bukovine manja je za 8,5 % od neobrađene, a za grabovinu je ona manja za 7,5 %. Smanjenje srednjih vrijednosti maksimalnih utezanja toplinski obrađene bukovine i grabovine u odnosu prema neobrađenoj još je veće. Maksimalno radijalno utezanje toplinski obrađene bukovine manje je za 7 %, maksimalno tangencijalno utezanje za 23,5 %, a maksimalno volumno utezanje za 19,3 % od istih fizikalnih svojstava neobrađene bukovine. Toplinski obrađena grabovina ima srednju vrijednost maksimalnoga radijalnog utezanja za 123 %, maksimalnoga tangencijalnog utezanja za 86 % i maksimalnoga volumnog utezanja za 99,5 % manju od istih fizikalnih svojstava neobrađene grabovine. Takvim smanjenjem maksimalnih utezanja u radijalnome i tangencijalnom smjeru toplinskom obradom grabovina postaje znatno prihvatljivija za izradu proizvoda za koje je važna dimenzionalna stabilnost.The investigation of physical properties of heat treated beech wood and hornbeam wood found that their average value is lower and significantly different from average values of physical properties of untreated beech wood and hornbeam wood. The average value of density in absolutely dry condition of heat treated beech wood is smaller by 8.5% from the untreated, and the hornbeam wood is smaller by 7.5%. Reduction of average values of maximum shrinkage of heat treated beech wood and hornbeam wood is even bigger in relation to the untreated wood. Maximum radial shrinkage of heat treated beech wood is smaller by 7%, maximum tangential shrinkage by 23.5% and maximum volumetric shrinkage by 19.3% compared to the same physical properties of untreated beech wood. Heat treated hornbeam wood has an average value of maximum radial shrinkage smaller by 123%, maximum tangential shrinkage by 86% and maximum volume shrinkage by 99.5% compared to the same physical properties of untreated hornbeam wood. With such reduction in the maximum shrinkage in radial and tangential direction using heat treatment, hornbeam becomes particulary suitable for making products where dimensional stability is important

Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials

Background Patients with chronic obstructive pulmonary disease (COPD) have few options for treatment. The efficacy and safety of the phosphodiesterase-4 inhibitor roflumilast have been investigated in studies of patients with moderate-to-severe COPD, but not in those concomitantly treated with longacting inhaled bronchodilators. The effect of roflumilast on lung function in patients with COPD that is moderate to severe who are already being treated with salmeterol or tiotropium was investigated. Methods In two double-blind, multicentre studies done in an outpatient setting, after a 4-week run-in, patients older than 40 years with moderate-to-severe COPD were randomly assigned to oral roflumilast 500 mu g or placebo once a day for 24 weeks, in addition to salmeterol (M2-127 study) or tiotropium (M2-128 study). The primary endpoint was change in prebronchodilator forced expiratory volume in 1s (FEV(1)). Analysis was by intention to treat. The studies are registered with ClinicalTrials.gov, number NCT00313209 for M2-127, and NCT00424268 for M2-128. Findings In the salmeterol plus roflumilast trial, 466 patients were assigned to and treated with roflumilast and 467 with placebo; in the tiotropium plus roflumilast trial, 371 patients were assigned to and treated with roflumilast and 372 with placebo. Compared with placebo, roflumilast consistently improved mean prebronchodilator FEV(1) by 49 mL (p<0.0001) in patients treated with salmeterol, and 80 mL (p<0.0001) in those treated with tiotropium. Similar improvement in postbronchodilator FEV(1) was noted in both groups. Furthermore, roflumilast had beneficial effects on other lung function measurements and on selected patient-reported outcomes in both groups. Nausea, diarrhoea, weight loss, and, to a lesser extent, headache were more frequent in patients in the roflumilast groups. These adverse events were associated with increased patient withdrawal. Interpretation Roflumilast improves lung function in patients with COPD treated with salmeterol or tiotropium, and could become an important treatment for these patients

In vivo labeling of peroxisomes by photoconvertible mEos2 in myelinating glia of mice

AbstractMutations of several genes encoding peroxisomal proteins have been associated with human diseases. Some of these display specific white matter abnormalities in the brain, although the affected proteins are ubiquitously expressed. To better understand the etiology of peroxisomal myelin diseases, we aimed to label these organelles in vivo and in a cell type specific fashion. We had previously shown that in oligodendrocytes and Schwann cells numerous peroxisomes reside in the cytoplasmic channels of “non-compacted” myelin. These organelles are smaller and biochemically distinct from non-myelin peroxisomes. Targeting peroxisomal functions in various cell types of the brain has demonstrated that oligodendroglial peroxisomes are specifically important for long-term integrity of the CNS. To visualize myelin peroxisomes in intact cells and tissues by live imaging, we have generated a novel line of transgenic mice for the expression of fluorescently tagged peroxisomes specifically in myelinating glia. This was achieved by modifying the gene for a photoconvertible mEos2 with a peroxisomal targeting signal type 1 (PTS1) and generating a fusion gene with the myelin-specific Cnp1 promoter. In the brain of resulting transgenic mice, peroxisomes are selectively labeled in oligodendrocytes. In this novel genetic tool, photoconversion of single peroxisomes from green to red fluorescence can be used to monitor the fate of single organelles and to determine the dynamics of PTS1-mediated protein import in the context of myelin diseases that affect peroxisomal functions